Introduction
============

In recent decades the incidence of thyroid cancer has increased steadily and consistently in many developed countries,[@ref1] most notably in South Korea, where the incidence increased by more than sevenfold, from 6.3 per 100 000 population in 1999 to 47.5 per 100 000 population in 2009.[@ref2] During that time, thyroid cancer became the most commonly diagnosed cancer in 2004 for women, and in 2009 for men and women combined.[@ref2] [@ref3] South Korea has the highest incidence of thyroid cancer in the world,[@ref4] which has raised public concern about the potential cause and also about the financial burden on the national healthcare system. The economic burden of thyroid cancer in South Korea increased about sevenfold, from \$257m (£207m; €232m) in 2000 to \$1724m in 2010,[@ref5] and outcomes could be similar for other countries. In the United States, for example, the incidence of thyroid cancer is expected to surpass that of colorectal cancer, to become the fourth most common malignancy by 2030.[@ref6] As such, the economic burden of well differentiated thyroid cancer in the United States is estimated to increase from more than \$1.6b in 2013 to more than \$3.5b in 2030.[@ref7] Overdiagnosis is considered the most plausible explanation for this "epidemic" of thyroid cancer worldwide, especially in South Korea.[@ref8] [@ref9] Thyroid cancer related mortality has remained stable for several decades,[@ref1] [@ref2] despite there being no major improvement in treatment, as exemplified by the trend in thyroid cancer incidence and mortality in South Korea (fig 1[](#f1){ref-type="fig"}).[@ref10] Further evidence shows a close correlation between the incidence rate of thyroid cancer and rates of screening for thyroid cancer by ultrasonography. In South Korea, previous studies reported a good correlation between the incidence of thyroid cancer in 2009 and screening rates in 2008 and 2009.[@ref8] [@ref11]

![**Fig 1** Trends in incidence of and mortality from thyroid cancer in South Korea, 1999-2012. The age standardised rates use Segi's world standard population](pars028305.f1_default){#f1}

Some investigators have, however, questioned the idea that overdiagnosis is the main cause of the current notable increase in cases of thyroid cancer.[@ref12] [@ref13] [@ref14] In a registry based cancer study,[@ref12] investigators observed that the incidence of both small and large thyroid tumours and the incidence of intrathyroidal and extrathyroidal cancers[@ref12] substantially increased from 1983 to 2006 in the United States. The researchers concluded that improved detection does not fully explain the rising incidence of thyroid cancer.[@ref12] In Australia, an increase in thyroid cancer at early and advanced stages was observed across a range of sociodemographic groups.[@ref13] Furthermore, there were no substantial differences in tumour size, invasion, lymph node involvement, or distant metastasis between incidentally and non-incidentally diagnosed thyroid cancers in the United States.[@ref14] In this nationwide epidemiological study we investigated the recent increase in cases of thyroid cancer in relation to the methods used to detect tumours.

Methods
=======

To investigate the reasons for the rapid increase in incidence of thyroid cancer in South Korea, in 2010 the Korea Central Cancer Registry conducted National Epidemiologic Survey of Thyroid cancer (NEST), which was designed to collect a representative sample of people with a diagnosis of thyroid cancer in 1999, 2005, or 2008. The study methods have been described previously,[@ref15] and the dataset is available on request (<http://kccrsurvey.cancer.go.kr/index.do>**)**.

We selected the study population from the registry database of all registered patients with thyroid cancer (3342 in 1999, 12 659 in 2005, and 26 890 in 2008). To do this, we used a two stage sampling method. Firstly, we used a probability-proportional-to-size method that was stratified by region in a given year to select 24 hospitals. Then we used a systematic sampling method to randomly select cases within each hospital. The number of cases diagnosed in 1999 and 2005 was smaller than in 2008, thus we applied different sampling proportions for each study year (33% in 1999, 22% in 2005, and 11% in 2008).

Using a predesigned data collection form, we collected basic personal variables from medical records. These included age and sex, and tumour related variables, such as tumour size, histological type, status of nodal and distant metastases, tumour stage (American Joint Committee on Cancer, cancer staging manual, sixth edition,[@ref16] Surveillance, Epidemiology, and End Results (SEER) summary staging manual[@ref17]), and the way in which the tumour was detected. The SEER summary stage grouped thyroid cancers into three major categories---localised, regional, and distant. The regional stage includes regional by direct extension only, only regional lymph nodes involved, and regional by both direct extension and regional lymph node involvement.[@ref17]

In our study, we further categorised the regional stage into five subgroups according to lymph node involvement (yes or no) and the degree of extrathyroidal extension (none, minimal, or gross).[@ref16] [@ref18] The way in which a tumour was detected was classified as screen detected (through cancer screening as recorded in medical records), clinically detected (by investigation of symptoms associated with thyroid disease, including thyroid cancer), and unspecified (or unknown). The histological subtypes of thyroid cancer were classified according to the *International Classification of Diseases for Oncology*, third edition[@ref19] as papillary carcinoma, medullary carcinoma, follicular carcinoma, anaplastic carcinoma, and others.[@ref20]

Of 6846 patients selected at the first stage (1103 in 1999, 2785 in 2005, and 2958 in 2008), we excluded 1050 cases from the final analysis. These included 960 cases where the hospital refused to disclose medical records, and 90 cases with insufficient data in the medical records. Overall, 5796 patients were included in this study (891 in 1999, 2355 in 2005, and 2550 in 2008). To check whether the database of the National Epidemiologic Survey of Thyroid Cancer was comparable with the National Cancer Incidence Database, we compared the age and sex distribution (see supplementary table 1) and the estimated age standardised incidence of thyroid cancer (see supplementary table 2). The results from the two surveys were comparable for each given year.

Statistical analysis
--------------------

We estimated the age standardised incidence rate of thyroid cancer for the three methods of tumours detection (screen versus clinical versus unspecified) by tumour size and SEER summary stage, for 1999, 2005, and 2008. To estimate the age standardised incidence of thyroid cancer, we calculated a weighted frequency for each five year age group for each study year, and then divided the weighted frequency by the corresponding mid-year population. The age standardised incidence rate was estimated using the weights for the proportions of corresponding five year age groups in the world standard (using Segi's standard population).[@ref21] The 95% confidence interval was calculated per 100 000 population (assuming that a Poisson distribution is appropriate). We calculated the absolute differences in the incidence of thyroid cancer according to the method of tumour detection by tumour size, SEER summary stage, and the American Joint Committee on Cancer stage between 1999 and 2008.

The baseline characteristics are presented as means with standard deviations or numbers (percentages), by year of detection. We used one way analysis of variance to compare the differences in continuous variables by year and a χ^2^test to compare the differences in categorical variables by year. P values of less than 0.05 were considered statistically significant. All statistical analyses were performed using Stata 12.0 (StataCorp LP, TX) and SAS 9.3 (SAS Institute, Cary, NC).

Patient involvement
-------------------

This study is a retrospective medical chart review of patients selected from the national cancer registry database. There was no direct contact with patients or individuals. No patients were involved in setting the research questions or the outcome measures, nor were they involved in developing plans for recruitment, design, or implementation of the study. No patients were asked to advise on interpretation or writing up of results. The dataset for this study is available from <http://kccrsurvey.cancer.go.kr/index.do> on request.

Results
=======

Table 1[](#tbl1){ref-type="table"} shows the characteristics of the study population for each study year. Overall, 84.5% of the participants (n=5796) were women, and the mean (SD) age was 46.9 (12.4) years. The most common histological type (94.9%) was papillary carcinoma. The size of thyroid tumours steadily decreased from 1999 to 2008. The proportion of screen detected tumours increased from 15.0% in 1999 to 56.1% in 2008. The proportion of regional stage thyroid cancer increased from 47.7% in 1999 to 59.1% in 2008, while the proportion of localised SEER summary stage thyroid cancer remained stationary. The proportion of distant stage thyroid cancer decreased from 5.4% in 1999 to 1.3% in 2008.

###### 

Characteristics of study population. Values are numbers (percentages) unless stated otherwise

  Variables                                   Total         Year          P value^\*^                 
  ------------------------------------------- ------------- ------------- ------------- ------------- --------
  Overall                                     5796          891           2355          2550          
  Mean (SD) age (years)                       46.9 (12.4)   46.0 (14.3)   47.3 (12.5)   46.8 (11.6)   0.03
  Mean (SD) tumour size (mm)                  13.3 (11.7)   21.5 (15.9)   13.6 (11.1)   10.5 (9.0)    \<0.01
  Sex:                                                                                                0.01
   Men                                        898 (15.5)    136 (15.3)    328 (13.9)    434 (17.0)    
   Women                                      4898 (84.5)   755 (84.7)    2027 (86.1)   2116 (83.0)   
  Methods of detection†:                                                                              \<0.01
   Screening                                  2655 (45.8)   134 (15.0)    1090 (46.3)   1431 (56.1)   
   Clinical                                   1784 (30.8)   447 (50.2)    773 (32.8)    564 (22.1)    
   Unspecified                                1357 (23.4)   310 (34.8)    492 (20.9)    555 (21.8)    
  Histological type‡:                                                                                 \<0.01
   Follicular carcinoma                       173 (3.0)     62 (7.0)      66 (2.8)      45 (1.8)      
   Papillary carcinoma                        5500 (94.9)   779 (87.4)    2243 (95.2)   2478 (97.2)   
   Medullary carcinoma                        43 (0.7)      13 (1.4)      19 (0.8)      11 (0.4)      
   Anaplastic carcinoma                       26 (0.5)      15 (1.7)      6 (0.3)       5 (0.2)       
   Other                                      54 (0.9)      22 (2.5)      21 (0.9)      11 (0.4)      
  Regional lymph node involvement:                                                                    \<0.01
   No                                         2466 (42.6)   268 (30.1)    1012 (43.0)   1186 (46.5)   
   Yes                                        2047 (35.3)   319 (35.8)    799 (33.9)    929 (36.4)    
   Unknown                                    1283 (22.1)   304 (34.1)    544 (23.1)    435 (17.1)    
  Distant metastasis:                                                                                 \<0.01
   No                                         5380 (92.8)   774 (86.9)    2196 (93.3)   2410 (94.5)   
   Yes                                        34 (0.6)      15 (1.7)      14 (0.6)      5 (0.2)       
   Unknown                                    382 (6.6)     102 (11.4)    145 (6.1)     135 (5.3)     
  Extrathyroidal extension:                                                                           \<0.01
   No                                         2783 (48.0)   397 (44.5)    1194 (50.7)   1192 (46.7)   
   Yes                                        2593 (44.7)   357 (40.1)    993 (42.2)    1243 (48.8)   
   Unknown                                    420 (7.3)     137 (15.4)    168 (7.1)     115 (4.5)     
  Focality:                                                                                           \<0.01
   Unifocal                                   3810 (66.7)   554 (62.2)    1553 (65.9)   1703 (66.8)   
   Multifocal                                 1697 (29.3)   234 (26.3)    689 (29.3)    774 (30.3)    
   Unknown                                    289 (5.0)     103 (11.5)    113 (4.8)     73 (2.9)      
  American Joint Committee on Cancer stage:                                                           \<0.01
   I                                          3038 (52.4)   428 (48.0)    1249 (53.0)   1361 (53.3)   
   II                                         49 (0.9)      14 (1.6)      23 (1.0)      12 (0.5)      
   III                                        1036 (17.9)   97 (10.9)     373 (15.8)    566 (22.2)    
   IV                                         426 (7.3)     101 (11.3)    178 (7.6)     147 (5.8)     
   Unknown                                    1247 (21.5)   251 (28.2)    532 (22.6)    464 (18.2)    
  SEER summary stage:                                                                                 \<0.01
   Localised                                  2125 (36.6)   302 (33.9)    919 (39.0)    904 (35.5)    
   Regional                                   3176 (54.8)   425 (47.7)    1243 (52.8)   1508 (59.1)   
   Distant                                    126 (2.2)     48 (5.4)      45 (1.9)      33 (1.3)      
   Unknown                                    369 (6.4)     116 (13.0)    148 (6.3)     105 (4.1)     

SEER=Surveillance, Epidemiology, and End Results.

\*Calculated by one way analysis of variance for continuous variables and χ^2^test for categorical variables.

†Classified as screen detected (as recorded in medical records), clinically detected (through investigation of symptoms associated with thyroid disease, including thyroid cancer), and unspecified (or unknown).

‡Classified based on International Agency for Research on Cancer (international classification of diseases for oncology, third edition). Extrathyroidal extension was determined on the basis of the American Joint Committee on Cancer (cancer staging manual, sixth edition).

Change in incidence of thyroid cancer over time by tumour size
--------------------------------------------------------------

Table 2[](#tbl2){ref-type="table"} and figure 2[](#f2){ref-type="fig"} (top panel) show the changes in the estimated incidence of thyroid cancer by tumour size for each method of tumour detection during 1999-2008. The incidence of screen detected tumours less than 10 mm increased steeply, from 0.27 (95% confidence interval 0.22 to 0.31) per 100 000 population in 1999 to 15.00 (14.70 to 15.29) per 100 000 population in 2008, with an absolute difference of 14.73. The incidence of clinically detected tumours less than 10 mm also showed a modest increase, from 0.49 per 100 000 population in 1999 to 4.88 per 100 000 population in 2008 (absolute difference 4.39). There was only a fractional increase in the incidence of screen detected tumours 30 mm or more and no significant increase in the incidence of such tumours detected clinically (absolute difference 0.00, 95% confidence interval −0.27 to 0.27). Overall, 94.4% of the total increase was attributed to the higher incidence of tumours less than 20 mm. The increase in incidence of such tumours accounted for 99.9% of the increase in clinically detected thyroid cancer, compared with 93.7% of the increase in screen detected tumours.

###### 

Estimated age standardised incidences (95% confidence intervals)^\*^ of thyroid cancer by methods of tumour detection, tumour size, and SEER summary stage, 1999, 2005, and 2008

  Variables             1999                                        2005                     2008                                                                                                                 
  --------------------- --------------------- --------------------- --------------------- -- --------------------- --------------------- --------------------- -- ------------------------ ---------------------- ---------------------
  Tumour size (mm):                                                                                                                                                                                               
   \<10                 0.27 (0.22 to 0.31)   0.49 (0.43 to 0.55)   0.43 (0.37 to 0.49)      4.80 (4.63 to 4.97)   2.37 (2.25 to 2.49)   1.59 (1.49 to 1.69)      15.00 (14.70 to 15.29)   4.88 (4.71 to 5.05)    4.00 (3.84 to 4.15)
   10-20                0.32 (0.27 to 0.37)   0.82 (0.74 to 0.90)   0.50 (0.44 to 0.56)      3.39 (3.25 to 3.54)   2.41 (2.28 to 2.54)   1.00 (0.92 to 1.08)      6.86 (6.66 to 7.06)      2.85 (2.72 to 2.98)    1.63 (1.53 to 1.73)
   20-30                0.13 (0.10 to 0.16)   0.76 (0.68 to 0.83)   0.30 (0.26 to 0.35)      0.67 (0.60 to 0.73)   1.09 (1.00 to 1.17)   0.39 (0.34 to 0.44)      0.97 (0.90 to 1.05)      0.89 (0.81 to 0.96)    0.45 (0.40 to 0.50)
   ≥30                  0.17 (0.13 to 0.21)   0.97 (0.88 to 1.06)   0.32 (0.27 to 0.37)      0.32 (0.28 to 0.37)   1.05 (0.97 to 1.13)   0.32 (0.28 to 0.37)      0.61 (0.55 to 0.68)      0.97 (0.89 to 1.05)    0.42 (0.37 to 0.47)
   Unspecified          0.13 (0.10 to 0.16)   0.30 (0.25 to 0.35)   0.47 (0.41 to 0.53)      0.21 (0.17 to 0.24)   0.26 (0.21 to 0.30)   0.59 (0.53 to 0.65)      0.27 (0.23 to 0.31)      0.18 (0.15 to 0.21)    0.76 (0.69 to 0.83)
  SEER summary stage:                                                                                                                                                                                             
   Localised            0.42 (0.36 to 0.48)   1.16 (1.07 to 1.25)   0.56 (0.49 to 0.62)      4.16 (4.00 to 4.32)   2.80 (2.66 to 2.93)   1.19 (1.10 to 1.27)      8.84 (8.61 to 9.07)      3.76 (3.60 to 3.91)    1.73 (1.63 to 1.83)
   Regional             0.37 (0.32 to 0.42)   1.57 (1.46 to 1.68)   1.04 (0.95 to 1.13)      4.74 (4.57 to 4.91)   3.90 (3.74 to 4.06)   2.01 (1.89 to 2.12)      14.15 (13.86 to 14.44)   5.51 (5.33 to 5.70)    4.50 (4.33 to 4.66)
   Distant              0.09 (0.06 to 0.12)   0.21 (0.17 to 0.25)   0.06 (0.03 to 0.08)      0.17 (0.14 to 0.21)   0.20 (0.17 to 0.24)   0.03 (0.02 to 0.04)      0.17 (0.14 to 0.20)      0.19 (0.16 to 0.23)    0.15 (0.12 to 0.18)
   Unknown              0.13 (0.10 to 0.16)   0.39 (0.33 to 0.45)   0.37 (0.32 to 0.42)      0.32 (0.27 to 0.36)   0.27 (0.23 to 0.31)   0.67 (0.60 to 0.73)      0.55 (0.49 to 0.60)      0.30 (0.26 to 0.35)    0.87 (0.80 to 0.95)
  Total                 1.01 (0.89 to 1.13)   3.34 (3.13 to 3.55)   2.02 (1.86 to 2.18)      9.39 (9.07 to 9.71)   7.17 (6.89 to 7.45)   3.89 (3.68 to 4.10)      23.71 (23.22 to 24.20)   9.76 (9.44 to 10.09)   7.25 (6.98 to 7.52)

SEER=Surveillance, Epidemiology, and End Results.

\*Calculated per 100 000 population. Segi's world standard population was used for age standardisation.

![**Fig 2** Differences in age standardised incidence of thyroid cancer per 100 000 population during 1999-2008 and 2005-08 by tumour size (top panel) and by Surveillance, Epidemiology, and End Results (SEER) summary stage (bottom panel). Error bars represent 95% confidence intervals of differences in age standardised incidence](pars028305.f2_default){#f2}

About 60% of the absolute increase in thyroid cancer incidence between 1999 and 2008 occurred during 2005-08, especially for screen detected cases, where tumours were less than 20 mm.

Changes in incidence of thyroid cancer over time by SEER summary stage
----------------------------------------------------------------------

Table 2[](#tbl2){ref-type="table"} and figure 2[](#f2){ref-type="fig"} (bottom panel) show the changes in estimated incidence of thyroid cancer according to the SEER summary stage. Overall, between 1999 and 2008 there was a 6.7-fold (95% confidence interval 5.8-fold to 7.8-fold) increase in localised stage tumours and an 8.1-fold (7.2-fold to 9.2-fold) increase in regional stage tumours. This increase in regional stage tumours accounted for 61.6% of the total increase in thyroid cancer incidence between 1999 and 2008, and 35.5% of the total increase was due to the increase in localised stage tumours. The incidence of distant stage thyroid cancer, however, increased little between 1999 and 2008.

A large increase was observed in the incidence of screen detected localised and regional stage cancers. The incidence of screen detected localised stage cancer increased by 8.4-fold from 1999 to 2008, and clinically detected localised stage thyroid cancer increased by 2.6-fold during the same period. The incidence of screen detected regional stage cancer increased by 38.2-fold, from 0.37 per 100 000 population in 1999 to 14.15 per 100 000 population in 2008. The incidence of clinically detected regional stage cancer increased by 3.5-fold from 1999 to 2008. In contrast, there was only a fractional increase in the incidence of screen detected distant stage thyroid cancer, and there was no significant change in the incidence of clinically detected distant stage thyroid cancer (absolute difference −0.02, 95% confidence interval −0.14 to 0.10).

Subgroup analysis of regional SEER summary stage tumours
--------------------------------------------------------

The regional SEER summary stage includes tumours with regional lymph node involvement and those with extrathyroidal extension. To better understand the true nature of the increase in the incidence of regional stage tumours over time, we further analysed the regional stage thyroid tumours by lymph node involvement (yes or no) and the degree of extrathyroidal extension (none, minimal, gross) according to the detection method by year (table 3[](#tbl3){ref-type="table"} and fig 3[](#f3){ref-type="fig"}). Most of the increase in incidence of regional stage thyroid cancer was due to lymph node involvement, about two thirds of which were with minimal extrathyroidal extension and one third without extrathyroidal extension. For the tumours without lymph node involvement, minimal extrathyroidal extension accounted for virtually all of the increase between 1999 and 2008. In terms of tumour detection method, there was a greater increase in the incidence of screen detected regional stage thyroid cancer than clinically detected regional stage tumours (absolute difference 13.8 *v* 3.9), even for the tumours with lymph node involvement (absolute difference 8.3 *v* 2.2).

###### 

Estimated age standardised incidences (95% confidence intervals)^\*^ of thyroid cancer with regional stage by degree of extension and lymph node involvement according to methods of tumour detection, 1999, 2005, and 2008

  Lymph node involvement and extrathyroidal extension   1999                                        2005                     2008                                                                                                                
  ----------------------------------------------------- --------------------- --------------------- --------------------- -- --------------------- --------------------- --------------------- -- ------------------------ --------------------- ---------------------
  No lymph node involvement:                                                                                                                                                                                                                     
   Minimal extension                                    0.09 (0.05 to 0.12)   0.44 (0.36 to 0.52)   0.38 (0.30 to 0.45)      1.76 (1.62 to 1.90)   1.31 (1.19 to 1.43)   0.75 (0.66 to 0.84)      5.53 (5.30 to 5.77)      2.18 (2.03 to 2.33)   1.56 (1.43 to 1.69)
   Gross extension                                      0.01 (0.00 to 0.02)   0.03 (0.01 to 0.05)   0.01 (0.00 to 0.01)      0.11 (0.08 to 0.15)   0.10 (0.07 to 0.13)   0.00 (0.00 to 0.00)      0.05 (0.03 to 0.08)      0.02 (0.01 to 0.04)   0.02 (0.01 to 0.04)
  Subtotal†                                             0.10 (0.06 to 0.13)   0.47 (0.39 to 0.55)   0.38 (0.31 to 0.45)      1.87 (1.73 to 2.01)   1.41 (1.28 to 1.53)   0.75 (0.66 to 0.84)      5.59 (5.35 to 5.82)      2.20 (2.05 to 2.35)   1.58 (1.46 to 1.71)
  Lymph node involvement:                                                                                                                                                                                                                        
   None                                                 0.13 (0.09 to 0.18)   0.52 (0.43 to 0.60)   0.16 (0.11 to 0.20)      1.33 (1.21 to 1.45)   0.89 (0.79 to 0.99)   0.46 (0.39 to 0.53)      3.05 (2.87 to 3.23)      1.14 (1.02 to 1.25)   0.89 (0.80 to 0.99)
   Minimal extension                                    0.13 (0.09 to 0.17)   0.53 (0.44 to 0.61)   0.49 (0.41 to 0.57)      1.43 (1.30 to 1.55)   1.46 (1.33 to 1.59)   0.77 (0.68 to 0.86)      5.48 (5.24 to 5.72)      2.06 (1.91 to 2.21)   2.00 (1.86 to 2.15)
   Gross extension                                      0.01 (0.00 to 0.02)   0.05 (0.03 to 0.08)   0.01 (0.00 to 0.02)      0.12 (0.08 to 0.15)   0.14 (0.10 to 0.19)   0.03 (0.01 to 0.05)      0.04 (0.02 to 0.05)      0.11 (0.08 to 0.15)   0.02 (0.00 to 0.03)
  Subtotal‡                                             0.27 (0.21 to 0.33)   1.10 (0.98 to 1.22)   0.66 (0.57 to 0.75)      2.87 (2.70 to 3.05)   2.49 (2.32 to 2.66)   1.26 (1.14 to 1.38)      8.56 (8.27 to 8.86)      3.31 (3.12 to 3.50)   2.91 (2.74 to 3.09)
  Total                                                 0.37 (0.32 to 0.42)   1.57 (1.46 to 1.68)   1.04 (0.95 to 1.13)      4.74 (4.57 to 4.91)   3.90 (3.74 to 4.06)   2.01 (1.89 to 2.12)      14.15 (13.86 to 14.44)   5.51 (5.33 to 5.70)   4.50 (4.33 to 4.66)

\*Calculated per 100 000 population. Segi's world standard population was used for age standardisation.

†Represents age standardised incidence of regional stage thyroid cancer without regional lymph node involvement.

‡Represents age standardised incidence of regional stage thyroid cancer that involves regional lymph node.

![**Fig 3** Absolute change over time in incidence of regional stage thyroid cancer by lymph node involvement and degree of extrathyroidal extension according to detection methods. Error bars represent 95% confidence intervals of differences in age standardised incidence during study period](pars028305.f3_default){#f3}

Changes in tumour size over time by method of tumour detection
--------------------------------------------------------------

Overall, the median size of thyroid tumours decreased from 18 mm in 1999 to 8 mm in 2008 (see supplementary figure 1 and table 3). The size of screen detected tumours was notably smaller than that of clinically detected tumours (P\<0.01); however, the magnitude of the decrease in median tumour size over time was greater for the clinically detected tumours (20 mm to 9 mm) than for the screen detected tumours (14.5 mm to 8 mm).

Regional lymph node involvement by tumour size and method of tumour detection
-----------------------------------------------------------------------------

Supplementary table 4 shows the status of regional lymph node involvement by tumour size according to the methods of tumour detection. Overall, even tumours less than 10 mm were found to have regional lymph node involvement in more than one fifth of cases: 22.8% in 1999 and 28.4% in 2008. As the tumour size increased to 10-20 mm, 20-30 mm, and 30 mm or more, the proportion of cases with positive regional lymph node involvement increased accordingly. However, the method of tumour detection did not have any real impact on the status of regional lymph node involvement.

Discussion
==========

Our study shows that most of the recent increases in the incidence of thyroid cancer in South Korea was due to greater detection of small (\<20 mm) tumours, which accounted for 94.4% of the overall increase (34.4 per 100 000 population) in the estimated incidence of thyroid cancer between 1999 and 2008. This increase is likely to be associated with the widespread practice of screening for thyroid cancer using ultrasonography, which started in the early 2000s in South Korea.[@ref8] [@ref22] In our study, 97.1% of the increase in estimated incidence of thyroid cancer was due to greater detection of regional and localised stage tumours, for which five year relative rates of survival were 100.1% and 100.4%, respectively, in South Korea.[@ref23] This finding of more than 100% relative survival rates means that people who have thyroid cancer and who are more likely to be screened for the cancer might be healthier and have a lower risk of dying than the general population, even in those with regional stage thyroid cancer by Surveillance, Epidemiology, and End Results (SEER) summary stage.

The increase in the estimated incidence of screen detected tumours only accounted for 66.1% of the total increase in incidence of thyroid cancer between 1999 and 2008, and clinically detected tumours accounted for an additional 18.7% of the increase. Some might argue that this finding is inconsistent with the idea of overdetection as a major contributor to the recent thyroid cancer "epidemic." However, we believe the opposite to be true. Overdetection of clinically indolent thyroid cancers is the best explanation for the observed findings in our study.

In fact, routine ultrasound examination and biopsy of any thyroid nodule less than 10 mm is not recommended in the absence of high risk clinical features.[@ref24] Interestingly, the median size for clinically detected tumours was only 9 mm in 2008 (it was 20 mm in 1999), which was similar to the median size of 8 mm for screen detected tumours in 2008 (see supplementary figure 1). Practically, tumours of 8-9 mm are just too small for patients to notice or doctors to find at such high rates. To be palpable or to cause symptoms at such a size the tumours would all have to be located at the isthmus or external surface of the thyroid, or be invading or pressing on the trachea, recurrent laryngeal nerve, or oesophagus, which is extremely unlikely. This raises serious questions about the true nature of clinically detected thyroid cancer, because it is not possible that so many tumours of less than 20 mm were detected clinically.

Furthermore, about 60% of the total increase in thyroid cancer incidence between 1999 and 2008 occurred over just three years (2005-08), and the rising trend continued even after that period (fig 1)[](#f1){ref-type="fig"}. However, in 2014 a public awareness campaign was launched against routine screening for thyroid cancer, and within one year there was a 35% decrease in the number of thyroid cancer surgeries undertaken.[@ref25] Taken together with the accumulating data---which showed that mortality from thyroid cancer had remained stable for decades, despite the rapid increase in its incidence (fig 1[](#f1){ref-type="fig"})[@ref8] [@ref26]---our findings provide further evidence for overdetection as a major contributor to the current thyroid cancer "epidemic" in South Korea.

Strengths and weaknesses of this study
--------------------------------------

Our study is meaningful as a nationwide survey that shows the change in incidence of thyroid cancer over time using a representative random sample of patients from cancer registry data. In addition, the study enables a better understanding of the mechanisms by which the incidences of thyroid cancer have recently increased, by analysing the data according to the methods of tumour detection and detailed pathological findings, including the size of tumour and nodal status.

However, this study has some limitations. Our data might have a misclassification bias for methods of tumour detection, which could cause either underestimation or overestimation of the incidence rate in specific subgroups. However, in our study, we used sample weights to calculate an unbiased estimate after adjusting for the non-response units. Indeed, the estimated incidence from NEST data was similar to the real incidence from cancer registry data (see supplementary tables 1 and 2). In addition, the estimated proportion of clinically detected cases from our findings in 2008 was similar to those from the Korea National Cancer Screening Survey study in 2009.[@ref27] Nevertheless, because of the relatively short follow-up, we could not secure the long term survival outcome data, which is the inherent limitation of this study of thyroid cancer.

Comparison with other studies
-----------------------------

The reason for the increasing incidence of thyroid cancer in the past decade has been well debated and summarised in recent reviews.[@ref28] [@ref29] Many experts suggested that the increase was a result of imaging tools being used more often for screening[@ref8] [@ref9] [@ref11] [@ref26] [@ref30]; others called for more epidemiological studies searching for yet unidentified causal factors.[@ref12] [@ref13] [@ref14]

Some studies have shown that the incidences of small and large advanced stage thyroid cancer have increased.[@ref12] [@ref31] Furthermore, a study of data from tertiary referral hospitals in the United States reported that the proportion of incidentally detected thyroid tumours not associated with symptoms did not increase, despite the increasing number of thyroid cancer cases overall.[@ref32] One study found that tumour size, invasion, lymph node involvement, and distant metastasis in patients with thyroid cancer detected incidentally were no different from those in patients with non-incidentally detected cancer.[@ref14] These findings, however, could be explained by the indolent nature of well differentiated thyroid tumours, which can grow to be large and can go undetected (even with lymph node involvement, as shown in this study, and extrathyroidal extension) until it is discovered incidentally through imaging investigations.[@ref33]

To date, the only confirmed risk factor for thyroid cancer is exposure to ionising radiation.[@ref34] In South Korea, however, there were no discernible sources of additional radiation exposure other than the medical use of radioisotopes and diagnostic procedures, such as computed tomography.[@ref11] [@ref27] [@ref35] Even if there were some increases in the incidence of thyroid cancer as a result of all those environmental factors, their contribution would be small. If the steep increase in incidence of thyroid cancer in South Korea is not a result of overdetection, it is hard to find a reasonable explanation for our findings of a 20.1-fold increase in small tumours (\<10 mm) and an 8.1-fold increase in regional stage tumours over the period 1999 to 2008.

Overdetection starts at the macro level, with how healthcare service is paid for at the system level, and extends down to the micro level, with how pathological specimens are processed now compared with how they were examined 30 years ago.[@ref28] [@ref29] The increase in thyroid cancer incidence in South Korea coincides with the widespread use of ultrasound examination in local clinics, which followed reform of the nation's healthcare system in 2000. Many hospitals and clinicians encouraged routine health checks, which included the option of screening for thyroid cancer (for an additional fee, as this was not covered by national health insurance). A study of 10 major hospitals showed that the annual number of ultrasound examinations of the thyroid almost doubled between 2001 and 2004, and the annual number of examinations using ultrasound guided fine needle aspiration almost quadrupled during the same period.[@ref22] At the microscopic level, more careful examination of resected thyroid specimens could well have contributed to the increase in incidence of thyroid cancer.[@ref36]

Generally, only nodules of more than 1 cm are recommended for further evaluation.[@ref24] If there is no increase in size or evidence of clinical progression of the tumour, some investigators recommend clinical observation for small papillary thyroid cancers, because they do not usually develop so aggressively.[@ref37] [@ref38] [@ref39] [@ref40] In South Korea, there was no discrete guideline for further evaluation of thyroid nodules until 2010, when the Korean Endocrine Society published a new guideline recommending the use of fine needle aspiration cytology for thyroid nodules of more than 5 mm.[@ref41] However, because small papillary tumours are usually less aggressive there has been growing concern about the potential harm from side effects of unnecessary evaluation and subsequent treatment. Recently, a multidisciplinary expert committee, organised by the National Cancer Center Korea, developed a guideline for thyroid cancer screening. A consensus was that thyroid ultrasonography is not routinely recommended for healthy people.[@ref42]

Conclusion and policy implications
----------------------------------

Our study shows that the increase in the incidence of thyroid cancer in South Korea mainly resulted from overdetection, most likely as a result of widespread use of sensitive imaging tools (eg, ultrasound examination). Considering the increase in thyroid cancer incidence,[@ref1] [@ref2] the financial burden of using ultrasound to detect small tumours (and the often unnecessary subsequent surgery) is expected to rise rapidly.[@ref5] [@ref6] [@ref7] Concerted efforts are needed at national level to reduce unnecessary ultrasound examination of the thyroid in the asymptomatic general population, unless clinically indicated.

### What is already known on this topic

1.  An increase in the incidence of thyroid cancer with little change in mortality has been observed in most countries

2.  The increased incidence of thyroid cancer is mainly due to detection of small, well differentiated thyroid tumours

3.  Overdiagnosis is considered to be the most plausible explanation; however, some remain unconvinced and have questioned this idea

### What this study adds

1.  This nationwide study found that the increase in thyroid cancer cases was due to an increase in the incidence of small tumours, which were detected mainly through screening

2.  Screening for thyroid cancer can detect small tumours, as well as clinically indolent asymptomatic tumours with local extension and lymph node involvement
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